

First ASTar® evaluation in Abu Dhabi, United Arab Emirates

Q-linea AB (publ) (OMX: QLINEA) today announces the initiation of the first clinical evaluation of ASTar at Sheikh Kalifa Medical City, Abu Dhabi (UAE).

This is the first ASTar evaluation in the Gulf Cooperation Council Region following recent clearance by the local authorities. The evaluation will include patient specimens, and it is being conducted in preparation for a ramp up of routine rapid antibiotic susceptibility testing (rapid AST).

“We are very pleased with how quickly projects are progressing in the Region thanks to the highly professional work done by AMICO Group, our partner in the Region. Given the high interest in rAST demonstrated during congresses and other customer interactions, we expect to initiate further evaluations in the region in the near future” said Franco Pellegrini, VP Sales EMEA at Q-linea.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[First ASTar® evaluation in Abu Dhabi, United Arab Emirates](#)